Back to Authors

Nowakowski, Grzegorz S.

https://orcid.org/0000-0002-6955-9393

A5061713890 | I1330342723

Mayo Clinic

Citations 513

Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9882-9884

10.1182/blood-2022-168152

A Multi-Center Study: Outcomes Among Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with CD20 Loss

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9510-9511

10.1182/blood-2022-158825

Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1921-1923

10.1182/blood-2022-164692

Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1934-1936

10.1182/blood-2022-165207

Outcomes with Immunochemotherapy Plus Radiation Versus Immunochemotherapy Alone in Stage I Diffuse Large B-Cell Lymphoma: A Retrospective Study

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3829-3830

10.1182/blood-2022-171148

Time to Complete Response within 24 Months As a Good Surrogate Marker of 8 Year-Progression Free Survival in Extranodal Marginal Zone Lymphoma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3583-3584

10.1182/blood-2022-169805

Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6517-6519

10.1182/blood-2022-165419

Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2056-2058

10.1182/blood-2022-169433

Molecular Landscape of Primary Refractory DLBCL

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9221-9223

10.1182/blood-2022-156497

Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9475-9477

10.1182/blood-2022-162774